ReviewOncoimmunology2014
Trial Watch: Radioimmunotherapy for oncological indications.
Review in Oncoimmunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 53 citations in OpenAlex.
- Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration.Blood advances · 2024Article
- Targeting circulating tumor cells to prevent metastases.Human cell · 2024Review
- Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control.Journal for immunotherapy of cancer · 2023Article
- Alloantigen-activated (AAA) CD4Journal of experimental & clinical cancer research : CR · 2021Article
- An autoimmune-based, paraneoplastic neurologic syndrome following checkpoint inhibition and concurrent radiotherapy for merkel cell carcinoma: case report.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020Article
- Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.Hepatology international · 2020Article
- Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade.Frontiers in immunology · 2020Review
- Radiotherapy in Combination With Cytokine Treatment.Frontiers in oncology · 2019Review
- Radiotherapy as a New Player in Immuno-Oncology.Cancers · 2018Review
- A Functional Signature Ontology (FUSION) screen detects an AMPK inhibitor with selective toxicity toward human colon tumor cells.Scientific reports · 2018Article
- Metabolic reprogramming by Dichloroacetic acid potentiates photodynamic therapy of human breast adenocarcinoma MCF-7 cells.PloS one · 2018Article
- Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging.Oncotarget · 2016Article
- Combination of Radiotherapy and Targeted Agents in Brain Metastasis: An Update.Current treatment options in neurology · 2016Review
- Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Oncoimmunology · 2016Review
- The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermia.Oncoimmunology · 2016Article
- Trial Watch-Immunostimulation with cytokines in cancer therapy.Oncoimmunology · 2016Review
- Trial Watch-Oncolytic viruses and cancer therapy.Oncoimmunology · 2016Review
- Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation.Frontiers in oncology · 2016Review
- Article
- Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma.Oncoimmunology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the past two decades, it has become increasingly clear that the antineoplastic effects of radiation therapy do not simply reflect the ability of X-, β- and γ-rays to damage transformed cells and directly cause their permanent proliferative arrest or demise, but also involve cancer cell-extrinsic mechanisms. Indeed, among other activities, radiotherapy has been shown to favor the establishment of tumor-specific immune responses that operate systemically, underpinning the so-called 'out-of-field' or 'abscopal' effect. Thus, ionizing rays appear to elicit immunogenic cell death, a functionally peculiar variant of apoptosis associated with the emission of a particularly immunostimulatory combination of damage-associated molecular patterns. In line with this notion, radiation therapy fosters, and thus exacerbates, the antineoplastic effects of various treatment modalities, including surgery, chemotherapy and various immunotherapeutic agents. Here, we summarize recent advances in the use of ionizing rays as a means to induce or potentiate therapeutically relevant anticancer immune responses. In addition, we present clinical trials initiated during the past 12 months to test the actual benefit of radioimmunotherapy in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.